계명대학교 의학도서관 Repository

Antiviral treatment for hepatitis B virus recurrence following liver transplantation

Metadata Downloads
Author(s)
김태석
Alternative Author(s)
Kim, Tae Seok
Publication Year
2013
Abstract
The purpose of this study was to identify the factors associated
with the recurrence of hepatitis B virus (HBV) following liver
transplantation (LT) for HBV-related disease and to recognize the
outcome of treatment for HBV recurrence with oral nucleos(t)ide
analogues. Six hundred and sixty-seven LTs were performed for HBsAgpositive
adult patients in our institute from 1996 to 2010. HBV
prophylaxis was performed by hepatitis B immunoglobulin (HBIG)
monotherapy or HBIG and entecavir combination therapy. There were
63 cases (11.4%) of HBV recurrences during a median follow-up of
51 months. The median time to HBV recurrence was 22 months. A
preoperative HBV DNA load of more than 105 IU/mL, HBIG
monotherapy, and hepatocellular carcinoma in the explant liver were
independent risk factors for HBV recurrence following LT in
multivariate analysis. Patient survival at 10 yr was 54.2% for HBVrecurrent
patients. Among patients with HBV recurrence, HBsAg
seroclearance was achieved in 13 patients (20.6%), but HBsAg
seroclearance did not affect survival in these patients after the recurrence
of HBV (p = 0.28). The recurrence of HBV led to graft failure in six
cases. HBV recurrence should be prevented by strict management of
pre-transplant HBV viremia and an effective post-transplant HBV
prophylaxis.
Department
Dept. of Surgery (외과학)
Publisher
School of Medicine
Citation
Clinical Transplantation, Vol.27(5) : E597-E604, 2013
Type
Article
ISSN
0902-0063
DOI
10.1111/ctr.12212
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35526
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.